We are an innovative biopharmaceutical start-up dedicated to developing cutting-edge, personalized treatments for cancer and chronic viral diseases. Our lead product is designed to target not only cancer and virus-infected cells, but also chemotherapy-resistant cancer stem cells and viral reservoirs, which are believed to drive disease recurrence. This therapeutic approach stands out for its enhanced anti-tumor efficacy and the absence of severe side effects, offering a unique and transformative solution for patients.
The company is now part of the Takeda Pharmaceuticals portfolio.
In addition to our product development efforts, we now offer expert consultancy services. Leveraging our deep knowledge and experience in biopharmaceutical innovation, we provide strategic guidance to companies and organizations in the healthcare and life sciences sectors, helping them navigate complex challenges and accelerate the development of novel therapeutics.
Company Details
- Founded
- -
- Address
- Lisbon, Pt
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Cellular Therapies, Immunotherapies, Oncology, Immunology, Regulatory Affairs, Startup Advisory, IP Management, Healthcare Fundraising, Healthcare Innovation, Fractional C-Suite Services.
- HQ
- Lisbon
Lymphact Questions
Lymphact's LinkedIn profile is https://pt.linkedin.com/company/lymphact
Lymphact's industry is
Biotechnology Research
Lymphact's top competitors are
Immunethep,
St Innovative Diagnostics Ltd.,
Express Tech,
Rhemastem Srls,
Novartis Portugal,
Synchrony,
Seal Biosciences,
Tzientzia,
Breakthrough Health, Inc.,
Bsim Therapeutics.
Lymphact's categories are Biotechnology Research
Lymphact's founding year is 2013
